Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Return on Invested Capital (2022 - 2025)

Historic Return on Invested Capital for Gyre Therapeutics (GYRE) over the last 8 years, with Q3 2025 value amounting to 0.06%.

  • Gyre Therapeutics' Return on Invested Capital rose 9300.0% to 0.06% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.06%, marking a year-over-year increase of 9300.0%. This contributed to the annual value of 0.28% for FY2024, which is 29600.0% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Return on Invested Capital of 0.06% as of Q3 2025, which was up 9300.0% from 0.05% recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Return on Invested Capital ranged from a high of 12.25% in Q4 2023 and a low of 2.35% during Q1 2022
  • Its 4-year average for Return on Invested Capital is 0.88%, with a median of 0.06% in 2022.
  • As far as peak fluctuations go, Gyre Therapeutics' Return on Invested Capital soared by 121800bps in 2023, and later tumbled by -121300bps in 2024.
  • Quarter analysis of 4 years shows Gyre Therapeutics' Return on Invested Capital stood at 0.07% in 2022, then soared by 18484bps to 12.25% in 2023, then tumbled by -99bps to 0.12% in 2024, then plummeted by -47bps to 0.06% in 2025.
  • Its last three reported values are 0.06% in Q3 2025, 0.05% for Q2 2025, and 0.07% during Q1 2025.